Korean J Med.
2022 Aug;97(4):229-237. 10.3904/kjm.2022.97.4.229.
Chimeric Antigen Receptor-T Cell Therapy
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- KMID: 2532478
- DOI: http://doi.org/10.3904/kjm.2022.97.4.229
Abstract
- Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Engineered T Cell Receptor for Cancer Immunotherapy
- Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
- Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
- Chimeric antigen T cell receptor treatment in hematological malignancies
- Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation
